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Introduction {#sec001}
============

When cells experience nutrient starvation, they start to degrade themselves by a process called autophagy. During autophagy, membrane structures called autophagosomes are generated and enwrap their targets, including cytosolic proteins and organelle, and delivers them to the lysosome for degradation. The degradation products, including amino acids, are recycled to sustain cellular homeostasis. The discovery of a series of autophagy-related (Atg) proteins, which participate in the formation of an autophagosome, paved the way toward the explosive expansion of autophagy studies; these proteins provide tools for exploring autophagy, which is related to multiple physiological phenomena\[[@pone.0230156.ref001]\].

In particular, autophagy is closely connected to various diseases, including cancer, neurodegenerative diseases, and infections\[[@pone.0230156.ref002]\]. For example, autophagy plays a crucial role in promoting tumor survival and growth in progressing cancers\[[@pone.0230156.ref003]\],\[[@pone.0230156.ref004]\]. Consistent with this, administration of an autophagy inhibitor, hydroxychloroquine, dramatically reduces tumors size\[[@pone.0230156.ref005]\]. However, hydroxychloroquine has severe side effects, including damage to the retina\[[@pone.0230156.ref006]\]. Accordingly, the development of novel, safe, and feasible autophagy-modulating drugs has attracted a great deal of attention in both academic research and the pharmacological industry\[[@pone.0230156.ref007]\],\[[@pone.0230156.ref008]\].

Traditional herbal medicine is a potential source of autophagy modulators. In fact, multiple studies have reported the effects of crude drug on autophagy\[[@pone.0230156.ref009]\]. In Japan, there is a system of traditional therapy, Kampo, that utilizes mixtures of crude drugs\[[@pone.0230156.ref010]\]. After originating in traditional Chinese medicine (TCM), it was gradually adopted into a Japanese style over the past centuries, and is now widely accepted by the Japanese medical system as over-the-counter or prescription drugs. Kampo medicines are combinations of multiple crude drugs with standardized dried extract formulations. Although its effects on a variety of diseases are appreciated, the underlying mechanisms remain mostly unclear. Because it is already accepted as a prescribed drug, Kampo will be relatively easy to apply to the clinical phase as drug repositioning after another efficacy like autophagy modulator. Furthermore, Kampo medicines are generally low-cost and have limited side effects, which makes their application more attractive.

In this study, we screened 128 Kampo medicines to search for autophagy modulators. In addition to the aforementioned expectation of future clinical application, knowledge of the detailed mechanisms by which Kampo interferes with autophagy will provide insight into the regulation of autophagy. To date, very few studies have focused on the relationship between Kampo and autophagy\[[@pone.0230156.ref011]\],\[[@pone.0230156.ref012]\]. We took advantages of our original tf-LC3 screening system, which could quantitatively estimate the effect of each drug on autophagy\[[@pone.0230156.ref013]\]. We identified TJ-35/Shigyakusan as a potent autophagic inhibitor, and found that it perturbs the calcium-dependent mechanism of autophagy induction.

Materials and methods {#sec002}
=====================

Cell culture {#sec003}
------------

HeLa cells were obtained from the stock of Yoshimori Lab (Osaka University) \[[@pone.0230156.ref014]\]. All cell lines were cultured with Dulbecco's modified Eagle's medium (DMEM) high glucose (D6429, Sigma-Aldrich) supplemented with heat-inactivated 10% FBS (F7524, Sigma-Aldrich) in 5% CO~2~ at 37°C. For starvation treatment, cells were gently washed twice with phosphate-buffered saline (PBS) and cultured in Earle's Balanced Salts solution (EBSS) (E3024, Sigma-Aldrich) for the indicated times. For the experiments regarding calcium influx from the medium, Hank's Balanced Salt Solution without calcium (HBSS, 14175--095 Gibco) and 20 mM HEPES buffer (1 mol/I-HEPES Buffer Solution pH 7.1\~7.5 17557--94 Nacalai Tesque) was used. For LC3 flux assays, 125 nM of bafilomycin A~1~ (023--11641, Wako) was added. For performing the aggrephagy experiment, 5 μg/mL puromycin was used (160--23151, Wako). For inhibiting calcineurin, 20 μM cyclosporin (TCI C2408) was used. HeLa cells stably expressing ULK1-EGFP \[[@pone.0230156.ref015]\], GFP-Atg5, GFP-WIPI1, tf-LC3 \[[@pone.0230156.ref013]\] or GFP-TFEB \[[@pone.0230156.ref016]\], described previously, were constructed using pMRX retroviral vector \[[@pone.0230156.ref017]\]. For retrovirus preparation, plasmids were transiently transfected into Plat-E cells using Lipofectamine 2000 (52887, Invitrogen). Related plasmids were transiently co-transfected with envelope vector pVSV-G \[[@pone.0230156.ref018]\]. After 36 hours, the retrovirus was harvested for infection. Stable transfection was established by retroviral infection using polybrene and selection in 2 μg/mL puromycin (160--23151, Wako).

Kampo extract preparation and screening {#sec004}
---------------------------------------

Kampo medicines were obtained from Tsumura, Tokyo, Japan. Ingredients of each Kampo are available at STORK (Standards of Reporting Kampo products) (<http://mpdb.nibiohn.go.jp/stork/>) maintained by the National Institute of Health Sciences (NIHS) of Japan. Each Kampo extract was soaked in water at 40 mg/mL in a 1.5 mL tube, and incubated at 98°C for 5 min. Debris was sedimented by centrifugation at 20,400 *g* for 10 min, and supernatants were aliquoted and stored at -20°C and used for further analysis.

For the analysis of TJ-35 (Shigyakusan) ingredients, 5.0g of Bupleurum root (004217010 Tochimoto Tenkaido), 4.0 g of Peony root (005316008 Tochimoto Tenkaido), 2.0 g of Immature Orange (002419002 Tochimoto Tenkaido), and 1.5 g of Glycyrrhiza (002018007 Tochimoto Tenkaido) were either boiled together or in one of the several combinations with omitting one ingredient in 500 mL of water, until it decreased to 250 mL. The supernatants were vaporized using a vacuum lyophilizer (LABCONCO) to produce extract powders.

Ninety-six-well glass-bottom plates (655891, Greiner Bio-One) were coated with 0.1 mg/mL collagen (Cell matrix Type I-C, Nitta Gelatin). HeLa-Kyoto cells stably expressing tf-LC3, seeded at 3,000 cells/well, were cultured with 100 μL of DMEM supplemented with 10% FBS in 5% CO~2~ at 37°C for 24 hours. One microliter of each Kampo extract (final, 400 μg/mL) was added to the medium, and incubated for the indicated period. Torin-1 (final, 250 nM) was used as a control for autophagy induction. Bafilomycin A~1~ (final, 125 nM) was used as a control for inhibition of autophagy. Cells were washed with PBS and fixed with 4% paraformaldehyde at room temperature for 20 min, and washed again with PBS. The samples were imaged using a CQ1 confocal quantitative image cytometer (Yokogawa). The intensity GFP or RFP signals in each view field was measured using the CQ1 Measurement software (Yokogawa).

Antibodies {#sec005}
----------

The following antibodies were used for immunoblotting and immunostaining: rabbit anti-LC3 (PM036, MBL) 1/1000(IB) 1/500(IS); rabbit anti-phospho-ULK1 (Ser757) (6888S, Cell Signaling) 1/1000: rabbit anti-TFEB (4240S, Cell Signaling) 1/2000; rabbit anti-mTOR(7C10) (2983S, Cell Signaling) 1/400; mouse anti-p70S6 kinase (49D7) (2708S, Cell Signaling) 1/1000; rabbit anti-4E-BP1 (9452S, Cell Signaling) 1/1000; mouse anti-tubulin (T9026, Sigma-Aldrich) 1/10000; mouse anti-GFP (11814460001, Roche) 1/500; rabbit anti-p62 (SQSTM1) (PM045 MBL) 1/1000; HRP-conjugated anti-rabbit secondary antibody (7074S, Cell, Signaling) 1/10000; HRP-conjugated anti-mouse secondary antibody (1031--05, Southern Biotech) 1/10000.

Western blotting {#sec006}
----------------

Western blotting was conducted basically as reported^15^. Cells cultured in 6-well plates were washed twice with 2 mL iced-cold PBS, lysed by adding 100--200 μL of ice-cold lysis buffer \[50 mM Tris-HCl (pH7.5) 150 mM NaCl, 1% Triton X-100\] containing complete protease inhibitor cocktail (11873580001, Roche) and placed on ice for 20 min. Cell extracts were sedimented by centrifugation at 20,400 *g* for 10 min at 4°C. Protein concentration of supernatants was measured using the Protein Assay Bicinchoninate kit (06385--00, Sigma-Aldrich). Supernatants were mixed with 100--200 μL of sample buffer (2% SDS, 100 mM DTT, 50 mM Tris-HCl \[pH 6.8\], 5% glycerol, 0.001% bromophenol blue), incubated at 98°C for 5 min, and separated by SDS-PAGE. LC3 protein was detected using 15% polyacrylamide SDS-PAGE gels, which were made using the following regents: H~2~O 1.4 mL, 1.5 M Tris-HCl (pH 8.8) 1.5 mL, 30% acrylamide/bis-acrylamide 3 mL, 10% SDS 60 μL, 10% ammonium peroxydisulfate: (APS) 50 μL, tetramethyl ethylenediamine: (TEMED) 5 μL. Stacking gel was prepared using the following reagents: H~2~O 1.8 mL, 0.5 M Tris-HCl (pH 6.8) 750 μL, 30% acrylamide/bis-acrylamide 375 μL, 10% SDS 30 μL, 10% APS 30 μL, TEMED 5 μL). TFEB, S6K and 4EBP1 proteins detected using 10% polyacrylamide SDS-PAGE gels, which were made using the following reagents: H~2~O 2.4 mL, 1.5 M Tris-HCl (pH 8.8), 1.5 mL, 30% acrylamide/bis-acrylamide 2 mL, 10% SDS 60 μL, 10% APS 50 μL, TEMED 5 μL. ULK1 protein detected using 7.5% polyacrylamide SDS-PAGE gels, which were made using the following regents: H~2~O 2.9 mL, 1.5 M Tris-HCl (pH 8.8) 1.5 mL, 30% acrylamide/bis-acrylamide 1.5 mL, 10% SDS 60 μL, 10% APS 50 μL, TEMED 5 μL. The separated proteins were transferred to PVDF membranes (LC3: Immobilon-P, Merck Millipore; ULK1, TFEB, S6K, and 4EBP1: Hybond-P, Amersham) using transfer buffer (24 mM Tris base, 190 mM glycine, 20% methanol) by the wet transfer system (NA-1510B S/N 15J01, EIDO) at 150 mA for 1 hour. The membranes were blocked for 1 hour at room temperature in 1.0% skim milk in TBS-T (25 mM Tris base, 137 mM NaCl, 2.7 mM KCl, 0.16% HCl, 0.08% Tween 20, pH adjusted to 7.4). For phosphorylated proteins, 2.5% bovine serum albumin (A7906-50G, Sigma-Aldrich) in TBS-T was used as the blocking buffer. After blocking, the membrane was incubated for 1 hour with each primary antibody in blocking buffer at room temperature. The membrane was washed three times with TBS-T for 10 min and incubated at room temperature for 40 min with HRP-conjugated secondary antibody in blocking buffer, and then washed three times with TBS-T for 10 min. The membrane was incubated in the ECL Select western blotting detection reagent (GE Healthcare) for 5 min at room temperature. Signals were detected on a Gene Gnome-5 chemiluminescence detector (Syngene).

Microscopy {#sec007}
----------

For immunofluorescence, coverslips (12-mm round, No 1S thickness, Matsunami Glass) were placed into 24-well plates (142475, NUNC), coated with 0.1 mg/mL collagen (Cell matrix Type I-C, Nitta Gelatin) for 1 hour at room temperature, and washed with PBS. Cells were seeded on the coverslips and grown to 60--80% confluence. After incubation, the cells were washed with PBS at room temperature, fixed with 4% Paraformaldehyde Phosphate Buffer Solution (163--20145, FUJIFILM) for 20 min, and washed with PBS. Samples were permeabilized by incubation with 50 μg/mL digitonin (300410, Calbiochem) in 0.2% gelatin-PBS for 10 min, and washed twice with 0.2% gelatin-PBS. Samples were blocked with 0.2% gelatin-PBS for 30 min at room temperature and incubated with primary antibodies diluted in 0.2% gelatin-PBS for 1 hour at room temperature. After three washes using 0.2% gelatin-PBS, cells were incubated with secondary antibody diluted in 0.2% gelatin-PBS (Invitrogen), and washed three times with 0.2% gelatin-PBS. Samples were mounted on glass slides in 5 μL of mounting medium \[3.8 mM Mowiol 4--888 (81381 ALDRICH), 3.3 M non-fluorescent glycerol (075--04751 Wako), 0.2 M Tris-HCl pH 8.5, 2.5% 1.4-diazabicyclo\[2.2.2\]octane (D27802 Sigma-Aldrich)\]. For observation of fluorescent proteins, cells were washed with PBS once and fixed with 4% paraformaldehyde for 20 min at room temperature. The samples were washed with PBS twice, and mounted with mounting reagent. Microscopic images were acquired using a TCS SP8 (Leica, Wetzlar, Germany) confocal laser-scanning fluorescence microscope equipped with an objective lens (HC PL APO 63x/1.40 OIL CS2, Leica). Fluorescent puncta were counted using ImageJ. For analysis of GFP-TFEB, cells positive for fluorescence in the cytoplasmic and nuclear region were counted using ImageJ.

Proximity ligation assay {#sec008}
------------------------

Proximity ligation assay (PLA) was conducted using Duolink in situ-Fluorescence (Sigma-Aldrich) basically as reported. HeLa cells stably expressing ULK1-EGFP\[[@pone.0230156.ref015]\], GFP-TFEB\[[@pone.0230156.ref016]\] or transiently transfected with FLAG-S6K\[[@pone.0230156.ref016]\] were seeded on coverslips in 24-well plates. After culture to 60%--80% confluence on coverslips, the cells were subjected to starvation with or without TJ-35, fixed with 4% paraformaldehyde for 20 min, permeabilized with 50 μg/mL digitonin in 0.2% gelatin-PBS for 10 min, and then blocked with 0.2% gelatin in PBS for 30 min. Samples were incubated with primary antibodies including rabbit anti-mTOR (1:400), mouse anti-GFP (1:500), and an mouse anti-FLAG (1:400) diluted in 0.2% gelatin-PBS for 1 hour, and washed twice with PBS. Samples were incubated with PLA probes (anti-rabbit PLUS and anti-mouse MINUS) diluted in 0.2% gelation-PBS at 37°C for 1 hour, washed twice for 5 min with PLA wash buffer A, and incubated with PLA Ligation-Ligase solution at 37°C for 30 min. Samples were washed twice with PLA wash buffer A for 2 min, incubated with PLA Amplification--Polymerase solution for 100 min at 37°C, washed twice with PLA wash buffer B for 10 min, and washed with 0.01x wash buffer B for 1 min. Samples were mounted in Duolink II mounting medium containing DAPI (4',6-diamidino-2-phenylindole). Fluorescent puncta were counted using ImageJ.

RT qPCR {#sec009}
-------

Total RNA was extracted using TRIzol (BIO-38032, BIOLINE), and with treated with deoxyribonuclease (18068--015 Invitrogen). Reverse transcription was conducted using iScript^TM^ Adv cDNA Kit for RT-qPCR (1725038 Bio-Rad). Primer sequences for ATPV6 LAMP1\[[@pone.0230156.ref019]\] were described previously, and for GAPDH were (forward) `aatcccatcaccatcttcca` and (reverse) `tggactccacgacgtactca`. Relative expression levels were monitored using an Applied Biosystems StepOnePlus^TM^ with the Ct method.

\[Ca^2+^\] measurement {#sec010}
----------------------

For the Fluo-8 method, HeLa cells were seeded on glass-bottom dishes (D11530H MATSUNAMI) and incubated with medium containing 10 μmol/L Fluo-8 (21081 AAT Bioquest) at 37°C for 30 min. For the G-CaMP3 Method\[[@pone.0230156.ref020]\], a plasmid encoding G-CaMP3 was transfected into HeLa cells on coverslips and incubated for 30 min. For both methods, fluorescence images at 485 nm were acquired on SP-8. Fluorescence intensity inside the encircled ROI (5 μm in diameter) in the cytoplasmic region was measured using ImageJ. Calcium concentration was calculated as follows: \[Ca^2+^\] = K~d~(Fluo-8 or G-CaMP3)×(F-F~min~)/(F~max~-F). The K~d~ of Fluo8 is 389 nM, and the K~d~ of G-CaMP3 is 345 nM. F is the fluorescence signal intensity. F~max~ is the fluorescence signal intensity measured under \[Ca^2+^\] maximum in the presence of 1 μM ionomycin (095--05831 Wako). F~min~ is the fluorescence signal intensity measured under \[Ca^2+^\] minimum in the presence of BAPTA-AM (0373124 Nacalai Tesque) in HBSS (Hanks balanced salt solution, modified, H9394 Sigma-Aldrich) medium containing 10 mM HEPES (1 mol/I-HEPES Buffer Solution pH 7.1\~7.5 17557--94 Nacalai Tesque).

Statistical analysis {#sec011}
--------------------

Bar-graphs were drawn with Excel for the average and standard deviation of three experiments if associated. Box-and-whisker plots were drawn with R for Median (line) upper and lower quartiles (boxes) 1.5-interquartile range (whiskers). Unpaired two-tailed Student's t-test between two samples (ex. EBSS and EBSS plus TJ-35) using Excel and \* denotes p\<0.05.

Results {#sec012}
=======

Screening of Kampo for effects on autophagy {#sec013}
-------------------------------------------

First, we explored the effect of Kampo extracts on autophagic activity by taking advantage of tf-LC3, a trimeric chimera of GFP, RFP, and LC3, which is an autophagosomal membrane protein transported into the lysosome ([Fig 1A](#pone.0230156.g001){ref-type="fig"})\[[@pone.0230156.ref021]\]. As autophagy progresses, GFP signal is attenuated due to its sensitivity to the acidic environment of the lysosome, whereas the RFP signal is maintained\[[@pone.0230156.ref021]\]. Hela cells stably expressing tf-LC3 were cultured in the presence of 128 kinds of Kampo extract, and the signal intensity of GFP and RFP in each view field was measured after 24 hours ([Fig 1B and 1C](#pone.0230156.g001){ref-type="fig"}), 48 hours ([S1A Fig](#pone.0230156.s001){ref-type="supplementary-material"}), and 72 hours of incubation ([S1B Fig](#pone.0230156.s001){ref-type="supplementary-material"}). To determine Torin-1 and Bafilomycin A concentration, we followed standard treatment conditions described previously \[[@pone.0230156.ref021], [@pone.0230156.ref022]\]. For determining Kampo concentration, we pre-screened small scale samples (20 samples) with different concentrations (100, 200, 400 μg/ml), and the concentration of 400 μg/ml exerted the most prominent effects; accordingly, we adopted it. In comparison to vehicle control, some Kampo treatments decreased the GFP/RFP signal ratio at each time point, as did the known autophagy inducer, Torin-1\[[@pone.0230156.ref022]\]. These represent candidates for autophagy inducers that could be examined in future studies. On the other hand, three kinds of Kampo, TJ-35, TJ-122, and TJ-133, increased the GFP/RFP signal ratio at each time point, similar to the known autophagy inhibitor bafilomycin A~1~ \[[@pone.0230156.ref023]\].

![Screening for effects of Kampo on autophagy by tf-LC3 assay.\
**A**. Schematic diagram of tf-LC3 assay. **B**. Screening results of tf-LC3 assay upon treatment with 128 Kampo medicines. The signal intensity ratio of GFP/RFP in each view field after 24 h of incubation is presented in order of value. Average and standard deviation of three independent screenings are shown. Bafilomycin A~1~ and Torin1 were used as controls. **C.** Representative images of each sample of B.](pone.0230156.g001){#pone.0230156.g001}

To further narrow down the candidates, we cultured HeLa cells expressing tf-LC3 under starvation conditions for 6 hours in the presence of these Kampo. TJ-35 treatment significantly decreased the number of GFP- and RFP-positive puncta in starvation medium. These results suggest that TJ-35 affects starvation-induced autophagy. To explore the effect of TJ-35 on other types of autophagy, we investigated the effect on aggrephagy, which targets aggregated proteins\[[@pone.0230156.ref024]\]. When the cells were treated with puromycin, numerous protein aggregates were formed that were colocalized with p62, which is an adaptor protein recruited to protein aggregates ([S2 Fig](#pone.0230156.s002){ref-type="supplementary-material"})\[[@pone.0230156.ref025]\]. After puromycin was washed out, autophagy efficiently cleared protein aggregates ([S2 Fig](#pone.0230156.s002){ref-type="supplementary-material"}). The presence of TJ 35 did not affect aggrephagy, suggesting the specific effect of TJ-35 on starvation-induced autophagy.

TJ-35 suppresses autophagosome formation under starvation condition {#sec014}
-------------------------------------------------------------------

When tf-LC3--expressing HeLa cells were shifted from nutrient-rich medium (DMEM) to starvation medium (EBSS), the number of GFP puncta increased, primarily representing autophagosomes and forming autophagosomes, i.e., isolation membranes/phagophores ([Fig 2A](#pone.0230156.g002){ref-type="fig"})\[[@pone.0230156.ref013]\]. However, TJ-35 treatment decreased the number of GFP-LC3 and RFP-LC3 puncta ([Fig 2A](#pone.0230156.g002){ref-type="fig"}). We also observed endogenous LC3 by immunofluorescence, and again the number of LC3-positive puncta was decreased by TJ-35 treatment ([Fig 2B](#pone.0230156.g002){ref-type="fig"}). LC3 is covalently conjugated to phosphatidyl ethanolamine to yield the LC3-II form, which is eventually degraded in the lysosome; treatment with the lysosomal activity inhibitor bafilomycin A~1~ treatment inhibits this degradation, causing LC3-II to accumulate ([Fig 2C](#pone.0230156.g002){ref-type="fig"}) ([S3A Fig](#pone.0230156.s003){ref-type="supplementary-material"})\[[@pone.0230156.ref026]\]. Although LC3-I band was scarcely detected, the bands that appeared were confirmed to be LC3-II by comparing them with those of the MEF cell samples ([S3B Fig](#pone.0230156.s003){ref-type="supplementary-material"}). However, TJ-35 treatment suppressed this LC3-II accumulation ([Fig 2C](#pone.0230156.g002){ref-type="fig"}). Together, these results established that TJ-35 treatment suppressed autophagy progression.

![TJ-35 suppresses autophagy under starvation condition.\
**A**. Tf-LC3--expressing HeLa cells were treated with or without TJ35 for 4 h, shifted to DMEM or EBSS with or without TJ-35 for 2 h, and observed on SP-8. The graph above shows GFP-positive puncta per cell. Median: line; upper and lower quartiles: boxes; 1.5-interquartile range: whiskers. We counted 15 cells in three independent experiments. Bar represents 10 μm. The graph below shows the signal intensity ratio of GFP/RFP in each field of view after 6 h. **B**. HeLa cells were cultured in DMEM for 24 h, treated with or without TJ-35 for 4 h, and shifted to EBSS in the presence of TJ-35 for 2 h. The cells were immunostained with anti-LC3 antibody. The graph shows Alexa Fluor 488-positive puncta per cell. Median: line; upper and lower quartiles: boxes; 1.5-interquartile range: whiskers. We counted 25 cells in three independent experiments. Bar represents 10 μm. **C**. HeLa cells were treated with or without TJ35 in DMEM or EBSS, with or without bafilomycin A~1~, for 4 h. The lysates were assessed by Western Blotting with LC3 antibody. The graph shows the average and standard deviation of LC3 signal versus tubulin signal from three independent experiments. \* denotes p\<0.05 (unpaired two-tailed Student's t-test) between EBSS and EBSS plus TJ-35.](pone.0230156.g002){#pone.0230156.g002}

TJ-35, Shigyakusan, is composed of four types of crude drug, namely, bupleurum root, peony root, immature orange, and Glycyrrhiza. To assess the role of each ingredient, we omitted each ingredient while preparing TJ-35. Omission of any of the four crude drugs resulted in failure of autophagy suppression, indicating that the combination of these ingredients is critical ([S4 Fig](#pone.0230156.s004){ref-type="supplementary-material"}).

We next sought to determine whether TJ-35 affects autophagosome formation. Atg5 is a protein associated with forming autophagosomes (i.e., isolation membranes/phagophores), and is detached from the membrane after completion of autophagosome formation\[[@pone.0230156.ref027]\]. Therefore GFP-Atg5-- positive structures represent isolation membranes/phagophores. When HeLa cells expressing GFP-Atg5 were incubated in starvation medium, EBSS, GFP-Atg5--positive punctuate structures were observed, indicating that autophagosome formation was proceeding ([Fig 3A](#pone.0230156.g003){ref-type="fig"}). However, when TJ-35 was present in the medium, the number of GFP-Atg5--positive punctate structures was significantly reduced ([Fig 3A](#pone.0230156.g003){ref-type="fig"}). Ulk1 is a protein kinase that forms a protein complex with FIP200/RB1CC1, ATG101, and ATG13, and makes scaffolds when autophagosome formation is induced\[[@pone.0230156.ref028]\]. Hela cells expressing ULK1-EGFP contained punctate signals under starvation, but these signals were much less abundant following TJ-35 treatment ([Fig 3B](#pone.0230156.g003){ref-type="fig"}). WIPI1 is recruited to the isolation membranes/phagophores and autophagosome via its ability to bind phosphatidylinositol 3-phosphate\[[@pone.0230156.ref029]\]. The number of GFP-WIPI1--positive punctate structures under starvation was also decreased by TJ-35 treatment ([Fig 3C](#pone.0230156.g003){ref-type="fig"}). We also observed endogenous LC3 in the presence of Bafilomycin A1 by immunofluorescence. When the nutrient rich medium was changed to starvation medium in the presence of Bafilomycin A~1~, LC3-positive puncta accumulated. However, when TJ-35 was present in the medium, the number of LC3-positive punctate structures was significantly reduced despite the present of Bafilomycin A~1~ ([S5 Fig](#pone.0230156.s005){ref-type="supplementary-material"}).

![TJ-35 suppresses autophagosome formation under starvation condition.\
**A**. GFP-Atg5 expressing HeLa was treated with or without TJ-35 for 4 h, and then shifted to DMEM or EBSS with or without TJ-35 for 2 h. The graph shows GFP-positive puncta per cell. Median: line; upper and lower quartiles: boxes; 1.5-interquartile range: whiskers. We counted 25 cells in three independent experiments. Bar represents 10 μm. **B**. ULK1-EGFP expressing HeLa was treated with or without TJ-35 for 4 h and shifted to DMEM or EBSS with or without TJ-35 for 2 h. The graph shows GFP-positive puncta per cell. Median: line; upper and lower quartiles: boxes; 1.5-interquartile range: whiskers. We counted 25 cells in three independent experiments. Bar represents 10 μm. **C**. GFP-WIPI1--expressing HeLa cells were treated with or without TJ-35 for 4 h and shifted to DMEM or EBSS with or without TJ-35 for 2 h. The graph shows GFP-positive puncta per cell. Median: line; upper and lower quartiles: boxes; 1.5-interquartile range: whiskers. We counted 15 cells in three independent experiments. Bar represents 10 μm. \* denotes p\<0.05 (unpaired two-tailed Student's t-test) between EBSS and EBSS plus TJ-35.](pone.0230156.g003){#pone.0230156.g003}

Collectively, these data indicated that TJ-35 treatment suppresses autophagy at the step before autophagosome formation.

TJ-35 suppresses dephosphorylation of ULK1 and TFEB specifically among mTORC1 substrates {#sec015}
----------------------------------------------------------------------------------------

We therefore asked whether TJ-35 treatment affects mTORC1 activity, a protein kinase that pivotally regulates autophagy upstream of Atg proteins\[[@pone.0230156.ref030]\]. TFEB is a transcriptional factor, whose localization is under the control of mTORC1 activity. Under nutrient-rich conditions, mTORC1 is active, and TFEB is phosphorylated and retained in the cytoplasm, whereas under starvation, dephosphorylated TFEB translocates to the nucleus\[[@pone.0230156.ref031]\]. However, when cells were treated with TJ-35, TFEB was still mostly localized in the cytoplasm even though the cells were experiencing starvation ([Fig 4A](#pone.0230156.g004){ref-type="fig"}). Upon entering the nucleus, TFEB up-regulates transcription of lysosome- and autophagy-related genes, including ATPV6 and LAMP1\[[@pone.0230156.ref031]\]([Fig 4B](#pone.0230156.g004){ref-type="fig"}). However, TJ-35 treatment suppressed that up-regulation ([Fig 4B](#pone.0230156.g004){ref-type="fig"}). These data raised the possibility that inactivation of mTORC1 during starvation is abrogated by TJ-35 treatment.

![TJ-35 suppresses dephosphorylation of ULK1 and TFEB specifically among mTORC1 substrates.\
**A**. GFP-TFEB expressing HeLa cells were treated with or without TJ-35 for 4 h, and then shifted to DMEM or EBSS with or without TJ-35 for 2 h. Bar represents 10 μm. The graph shows quantification of GFP-TFEB that localized in the cytoplasm or nucleus. Percent of cells with cytoplasmic, nucleus or both. We counted 30 cells in three independent experiments. **B**. HeLa cells were treated with or without TJ-35 in DMEM or EBSS for 4 h, and then total RNA was extracted. Expression levels of ATPV6 and LAMP1 versus GAPDH were monitored by RT qPCR. The graph shows fold change. **CE**. HeLa cells were treated with or without TJ-35 for 4 h, shifted to DMEM or EBSS with or without TJ-35 or Torin-1 for 2 h, and then subjected to immunoblotting with anti-TFEB, anti-phosopho-S6K, anti-p70 kinase, anti-4E-BP1 and anti-Tubulin. The samples of C and E were derived from the same preparation. **D**. HeLa cells were treated with or without TJ-35 for 4 h, shifted to DMEM or EBSS with or without TJ-35 or Torin-1 for 2 h, and then subjected to immunoblotting with anti-phospho-ULK1(Ser757), anti-ULK1 and anti-Tubulin.](pone.0230156.g004){#pone.0230156.g004}

To further test this hypothesis, we examined other substrates of mTORC1. To this end, HeLa cells were cultured under starvation conditions with or without TJ-35 and subjected to western blot. Multiple sites on ULK1 protein kinase involved in autophagy, including serine-757, are dephosphorylated upon starvation and mTORC1 inhibition\[[@pone.0230156.ref032]\]. TJ-35 treatment suppressed this dephosphorylation ([Fig 4C](#pone.0230156.g004){ref-type="fig"}). The band size of TFEB was shifted down in response to starvation, indicative of dephosphorylation ([Fig 4D](#pone.0230156.g004){ref-type="fig"}). However, the downshift was significantly suppressed in the presence of TJ-35, consistent with the above result ([Fig 4D](#pone.0230156.g004){ref-type="fig"}). Unexpectedly, however, the other major mTORC1 substrates, ribosomal protein S6 kinase (S6K) were dephosphorylated normally even in the presence of TJ-35 ([Fig 4E](#pone.0230156.g004){ref-type="fig"})\[[@pone.0230156.ref033]\]. As for another substrate of mTORC1, western blotting with anti-translation initiation factor 4E-binding protein (4EBP1) antibody reacted with both phosphorylated and unphosphorylated 4EBP1, with the latter represented by the down-shift of the band size. Dephosphorylation of 4EBP1 was also unaffected by TJ-35 ([Fig 4E](#pone.0230156.g004){ref-type="fig"}). Collectively, these findings indicate that TJ-35 affects dephosphorylation of only some mTORC1 substrates, namely ULK1 and TFEB, which play pivotal roles in autophagy regulation.

TJ-35 specifically suppresses dissociation of ULK1 and TFEB from mTOR under starvation conditions {#sec016}
-------------------------------------------------------------------------------------------------

To substantiate the above results, we examined the physical association among mTORC1 and its substrates by the proximity ligation assay (PLA). In this experimental system, specific antibodies against two different antigens give rise to punctate fluorescent signals if the antigens are within 40-nm proximity\[[@pone.0230156.ref034]\]. HeLa cells stably expressing ULK1-EGFP cultured under nutrient-rich conditions were subjected to PLA using antibodies against GFP and the mTOR; 4.0 ± 1.1 fluorescent signals were detected per cell ([Fig 5A](#pone.0230156.g005){ref-type="fig"}). These signals represented mTOR-ULK1 proximal associations, as omitting either antibody abolished the signals ([S6 Fig](#pone.0230156.s006){ref-type="supplementary-material"}). These signals were less abundant (1.3 ± 1.1 per cell) under starvation conditions ([Fig 5A](#pone.0230156.g005){ref-type="fig"}). These support previous co-immunoprecipitation data showing that mTORC1 is associated with ULK1 under nutrient-rich conditions, and dissociates after starvation\[[@pone.0230156.ref035]\]. However, when cells were cultured with TJ-35, the reduction in the fluorescence signals under starvation conditions was suppressed, indicating that TJ-35 prevented the proteins from dissociating ([Fig 5A](#pone.0230156.g005){ref-type="fig"}). An interaction between TFEB and mTOR has also been reported\[[@pone.0230156.ref036]\]. HeLa cells stably expressing GFP-TFEB were subjected to PLA with anti-GFP and anti-mTOR antibodies. As with ULK1, we observed a nutrient-dependent association TFEB with mTOR, and TJ-35 treatment suppressed dissociation during starvation ([Fig 5B](#pone.0230156.g005){ref-type="fig"}). By contrast, although we also observed a nutrient-dependent association between mTOR and FLAG-S6K, we did not see any TJ-35--dependent suppression of dissociation during starvation ([Fig 5C](#pone.0230156.g005){ref-type="fig"})\[[@pone.0230156.ref037]\]. These results indicate that TJ-35 affect the dissociation between mTOR with ULK1/TFEB, but not with S6K, supporting the idea of a dephosphorylation defect specific to the former two substrates.

![TJ-35 specifically suppresses dissociation of ULK1 and TFEB from mTORC1 under starvation conditions.\
**A**. ULK1-EGFP--expressing HeLa cells were treated with or without TJ-35 for 4 h, and shifted to DMEM or EBSS with or without TJ-35 for 2 h, and subjected to PLA using anti-GFP and mTOR antibodies. We counted 15 cells counted in two independent experiments. **B**. GFP-TFEB--expressing HeLa cells were treated with or without TJ-35 for 4 h, shifted to DMEM or EBSS with or without TJ-35 for 2 h, and subjected to PLA using anti-GFP and mTOR antibodies. We counted 30 cells in two independent experiments. C. FLAG-S6K--expressing HeLa was treated with TJ-35 for 4 h and shifted to DMEM or EBSS with or without TJ-35 for 2 h, and subjected to PLA using anti-FLAG and mTOR antibodies. We counted 10 cells in two independent experiments. \* denotes p\<0.05 (unpaired two-tailed Student's t-test) between EBSS and EBSS plus TJ-35.](pone.0230156.g005){#pone.0230156.g005}

TJ-35 suppresses cytosolic Ca^2+^ increment under starvation conditions {#sec017}
-----------------------------------------------------------------------

TFEB dephosphorylation and nuclear translocation are suppressed by knockdown of the catalytic subunit (PPP3CB) of the calcineurin, a protein phosphatase activated by Ca^2+^\[[@pone.0230156.ref038]\]. We confirmed this point via a different assay. When cells were incubated with the calcium ionophore ionomycin (final, 3 μM), causing an influx of calcium from the medium into the cells, TFEB was dephosphorylated ([Fig 6A](#pone.0230156.g006){ref-type="fig"}). However, this dephosphorylation was inhibited by treatment with cyclosporin A, an inhibitor of calcineurin\[[@pone.0230156.ref039]\], in a dose-dependent manner ([Fig 6](#pone.0230156.g006){ref-type="fig"}). Similar results were obtained with NFAT, a well-established calcineurin substrate ([Fig 6](#pone.0230156.g006){ref-type="fig"})\[[@pone.0230156.ref040]\], supporting the idea that TFEB is a bona fide substrate of calcineurin. ULK1, S6K, and 4E-BP were not dephosphorylated by ionomycin treatment (data not shown).

![Cytosolic \[Ca^2+^\] increment induces TFEB dephosphorylation via calcineurin.\
HeLa cells expressing HA-NFAT (Addgene: 11107) were treated with ionomycin in DMEM for 1 h with or without the indicated concentration of cyclosporin A. Lysates were immunoblotted with anti-TFEB and anti-HA.](pone.0230156.g006){#pone.0230156.g006}

Accordingly, we investigated whether the cytosolic calcium concentration is affected by starvation. For this purpose, HeLa cells were stained with the fluorescent Ca^2+^ chemical probe Fluo-8\[[@pone.0230156.ref041]\]. Fluorescent signals increased under starvation conditions relative to nutrient-rich conditions ([Fig 7A](#pone.0230156.g007){ref-type="fig"}). Based on values from the positive control (ionomycin-treated cells) and negative control (BAPTA treatment), we calculated that the calcium concentration was about 196 nM under nutrient-rich conditions and 618 nM under starvation conditions ([Fig 7A](#pone.0230156.g007){ref-type="fig"}). To rule out the possibility that this is due to some artifact of Fluo-8, we employed another calcium probe, G-CaMP3, a GFP-based proteinaceous probe\[[@pone.0230156.ref020]\]. A similar increment was observed after the shift to starvation (353 nM) from nutrient-rich medium (88 nM) ([Fig 7A](#pone.0230156.g007){ref-type="fig"}). These results highlighted the novel observation that starvation conditions increase the cytosolic calcium concentration. We also treated the cells with ionomycin and cyclosporin A to see if any effects could be observed on autophagy. It has been reported that ionomycin treatment for 24 h results in massive accumulation of autophagosomes\[[@pone.0230156.ref042]\]. We treated the cells for 30 min, and consequently, ionomycin treatment in DMEM led to an accumulation of GFP-LC3, supporting Ca dependent autophagy induction mechanism ([S7 Fig](#pone.0230156.s007){ref-type="supplementary-material"}). In addition, cyclosporin A treatment in EBSS reduced GFP-LC3 formation, supporting the positive role of Calcineurin in autophagy induction ([S7 Fig](#pone.0230156.s007){ref-type="supplementary-material"}).

![TJ-35 suppresses cytosolic Ca^2+^ increment under starvation condition.\
**A**. HeLa cells were cultured with DMEM for 24 h, shifted to EBSS for 2 h. The cells were stained with Fluo-8 for 30 min. HeLa cells were transiently transfected with G-CaMP3 (Addgene: 22692) for 24 h, and shifted to EBSS for 2 h. For measuring Fmax, ionomycin was added to DMEM. For measuring Fmin, HeLa cells transiently transfected with G-CaMP3 were cultured and added ionomycin with BAPTA in HBSS. **B**. HeLa cells were cultured with DMEM for 24 h, shifted to EBSS with or without TJ-35. The cells were stained with Fluo-8 for 30 min. We counted 30 cells in three independent experiments. **C**. HeLa cells were transiently transfected with G-CaMP3 for 24 h, shifted to EBSS with or without TJ-35. We counted 30 cells in three independent experiments. **ABC**. Fluorescence intensity in ROI within cytoplasm was measured. Median: line; upper and lower quartiles: boxes; 1.5-interquartile range: whiskers. \* denotes p\<0.05 (unpaired two-tailed Student's t-test) between EBSS and EBSS plus TJ-35.](pone.0230156.g007){#pone.0230156.g007}

We then examined the effect of TJ-35, and found that the starvation-induced increment in cytosolic \[Ca^2+^\] was significantly suppressed by TJ-35 treatment in both the Fluo-8 ([Fig 7B](#pone.0230156.g007){ref-type="fig"}) and G-CaMP3 assays ([Fig 7C](#pone.0230156.g007){ref-type="fig"}). Thus, the autophagy- suppressive effect of TJ-35 could be attributed, at least in part, to this phenomenon.

To identify the source of the starvation-induced calcium influx, we investigated two possible major calcium sources: the extracellular medium and the endoplasmic reticulum\[[@pone.0230156.ref043]\]. Even when calcium in the medium was chelated with EDTA, starvation-induced calcium influx was normal, ruling out the possibility that the medium was the source ([Fig 8A](#pone.0230156.g008){ref-type="fig"}).

![Starvation induced calcium efflux from the ER mediated by the IP3 receptor.\
**A**. HeLa cells were cultured with 0.5 mM EDTA in EBSS for 90 min and then stained with Fluo-8 for 30 min. 15 cells were counted in three independent experiments. **B**. HeLa cells were treated with or without xestospongin C in DMEM or EBSS for 90 min, and then stained with Fluo-8 for 30 min. 15 cells were counted in three independent experiments. HeLa cells were transiently transfected with G-CaMP3 and shifted to DMEM or EBSS with or without xestospongin C for 2 h. 30 cells were counted in three independent experiments. Fluorescence intensity was measured in ROI within cytoplasm. Median: line; upper and lower quartiles: boxes; 1.5-interquartile range: whiskers. \* denotes p\<0.05 (unpaired two-tailed Student's t-test) between EBSS and EBSS plus drug treatment.](pone.0230156.g008){#pone.0230156.g008}

Xestospongin C is an inhibitor of the IP3 receptor, which is a major calcium release channel in the ER\[[@pone.0230156.ref044]\]. When cells were treated with Xestospongin C, starvation-induced calcium influx was severely defective in both the Fulo-8 and G-CaMP3 assays ([Fig 8B](#pone.0230156.g008){ref-type="fig"}). Collectively, these observations indicate that TJ-35 prevents starvation-induced calcium efflux from the ER mediated by the IP3 receptor.

Discussion {#sec018}
==========

In this study, we comprehensively screened Kampo medicines for effects on autophagy, and elucidated an inhibitory effect of Shigyakusan/TJ-35 on autophagy. Shigyakusan/TJ-35 is composed of dried extract of Bupleurum root, Peony root, Immature Orange, and Glycyrrhiza. TJ-35 is prescribed for various inflammatory diseases such as cholecystitis, pancreatitis and gastritis\[[@pone.0230156.ref045]\],\[[@pone.0230156.ref046]\]. The mechanism of action of TJ-35 appears to involve increased gastric mucosal levels of lipid peroxide\[[@pone.0230156.ref045]\]; prevention of the progress of gastric mucosal lesions\[[@pone.0230156.ref046]\], and scavenging of O~2~ generated by the hypoxanthine--xanthine oxidase system\[[@pone.0230156.ref045]\]. Although definitive correlation of these diseases with autophagy are still to be determined, it is known that acute pancreatitis is relieved by suppression of autophagy\[[@pone.0230156.ref047]\]. Suppression of autophagy by TJ-35 is anticipated to provide insight into the overall effect of this medicine.

We found that TJ-35 suppresses dephosphorylation of two mTORC1 substrates, TFEB and ULK1, both of which are critical for autophagy induction\[[@pone.0230156.ref048]\],\[[@pone.0230156.ref049]\]. Therefore, the suppressive effect of TJ-35 on autophagy could be reasonably attributed to this finding. The point of action cannot be assigned to general mTORC1 regulation, as dephosphorylation of two other mTORC1 substrates, S6K and 4E-BP, was not affected by TJ-35 ([Fig 4E](#pone.0230156.g004){ref-type="fig"}). Although the mechanism regarding ULK1 remains to be determined, we succeeded in narrowing down in the TFEB-related mechanism. TFEB is a bona fide substrate of calcineurin ([Fig 6](#pone.0230156.g006){ref-type="fig"})\[[@pone.0230156.ref038]\]. Calcium plays both pro-autophagy and anti-autophagy roles in a context-dependent manner, according to the triggering stimulus\[[@pone.0230156.ref050]\]. We revealed that the cytosolic calcium concentration is elevated upon shift to EBSS, and that elevation is suppressed by TJ-35 treatment ([Fig 7B and 7C](#pone.0230156.g007){ref-type="fig"}). Because this elevation flows from the ER, mediated by IP3 receptor, TJ-35 is likely to affect the IP3 receptor and/or its upstream regulator, including the IP3. Previous work showed that calcium pooled in the lysosome is extruded in response to starvation, which activates calcineurin\[[@pone.0230156.ref038]\]. That study proposed that the calcium concentration is elevated locally, in the vicinity of the lysosome. Although this model could be still viable, our results showed that the calcium concentration is elevated throughout the cytoplasm under starvation ([Fig 7](#pone.0230156.g007){ref-type="fig"}). Decuypere et al. reported that starvation treatment sensitizes the IP3 receptor when stimulated by several reagents, including ionomycin, tapshigargin, and ATP, supporting the idea that the IP3 receptor plays key roles in calcium elevation under starvation\[[@pone.0230156.ref051]\]. Further, they also showed that chelation of intracellular calcium by BAPTA-AM or inhibition of the IP3 receptor by xestospongin C suppressed autophagy under starvation\[[@pone.0230156.ref051]\]. These observations are in line with our results, and are consistent with a crucial role for calcium in starvation-induced autophagy. Thus, our results also suggest that calcium elevation is a key regulatory step in autophagy induction, and that TJ-35 is useful for pursuing this point in relation to regulation of autophagy. Further studies of the detailed mechanism and *in vivo* experiments should be performed in order explore the path to clinical application of TJ-35/Shigyakusan as an anti-autophagy modulator in diverse diseases, including cancer.

Supporting information {#sec019}
======================

###### Screening for an effect of Kampo on autophagy by tf-LC3 assay.

**A.B.** Screening results of tf-LC3 assay upon treatment with 128 Kampo medicines. The signal intensity ratio of GFP/RFP in each view field at 48 h (A) or 72 h (B) incubation is presented in order of its value. Average and standard deviation of three independent screens are shown. Bafilomycin A~1~ and Torin-1 were used as controls.

(PDF)

###### 

Click here for additional data file.

###### Assessment of an effect of TJ-35 on aggrephagy.

HeLa cells were cultured in DMEM with or without puromycin for 6 h, and after being washed out, further cultured in DMEM with or without TJ-35 for 17 h, and immunostained with anti-p62 on SP-8.

(PDF)

###### 

Click here for additional data file.

###### TJ-35 suppresses autophagy under starvation condition.

A. HeLa cells were treated with or without TJ35 in DMEM, with or without bafilomycin A~1~, for 4 h. The lysates were assessed by Western Blotting with LC3 antibody. B. Comparison of Band pattern of LC3 by western blotting: MEF and HeLa cells were cultured in DMEM or EBSS, with or without bafilomycin A~1~, for 4 h. The lysates were assessed by western blotting with antibodies against LC3 and tubulin

(PDF)

###### 

Click here for additional data file.

###### Analysis of TJ-35/Shigyakusan ingredients in autophagy.

Tf-LC3--expressing HeLa cells were cultured in DMEM with or without Shigyakusan and with extracts with omission of any of the four crude drugs for 4 h, shifted to DMEM or EBSS with or without the above combination of Shigaykusan ingredients for 2 h, and observed on SP-8. The graph below shows the signal intensity ratio of GFP/RFP in each field of view. \* denotes p\<0.05 (unpaired two-tailed Student's t-test) against EBSS only sample.

(PDF)

###### 

Click here for additional data file.

###### TJ-35 suppresses autophagosome formation under starvation condition.

HeLa cells were treated with or without TJ35 in DMEM or EBSS, with or without bafilomycin A~1~, for 4 h. The cells were immunostained with anti-LC3 antibody. The graph shows Alexa Fluor 488-positive puncta per cell. Median: line; upper and lower quartiles: boxes; 1.5-interquartile range: whiskers.

(PDF)

###### 

Click here for additional data file.

###### Specificity of PLA with ULK1 and TFEB from mTORC1.

ULK1-EGFP--expressing HeLa cells and GFP-TFEB--expressing HeLa were cultured in DMEM for 24 h, and subjected to PLA using either anti-GFP antibody or mTOR antibody or both. FLAG-S6K--expressing HeLa were cultured in DMEM for 24 h, and subjected to PLA using either anti-FLAG antibody or mTOR antibody or both.

(PDF)

###### 

Click here for additional data file.

###### Ca2+ increment induces autophagy and calcineurin inhibitor suppresses autophagy.

Tf-LC3--expressing HeLa cells were treated in DMEM or EBSS with 3 μM ionomycin or 20 μM cyclosporin A for 30 min. TJ-35 treatment condition was the same as above. Images were acquired on SP-8.

(PDF)

###### 

Click here for additional data file.

###### Full blot images-[Fig 2C](#pone.0230156.g002){ref-type="fig"}.

(PDF)

###### 

Click here for additional data file.

###### Full blot images-[Fig 4C](#pone.0230156.g004){ref-type="fig"}.

(PDF)

###### 

Click here for additional data file.

###### Full blot images-[Fig 4D](#pone.0230156.g004){ref-type="fig"}.

(PDF)

###### 

Click here for additional data file.

###### Full blot images-[Fig 4E](#pone.0230156.g004){ref-type="fig"}.

(PDF)

###### 

Click here for additional data file.

###### Full blot images-[Fig 6-1](#pone.0230156.g006){ref-type="fig"}.

(PDF)

###### 

Click here for additional data file.

###### Full blot images-[Fig 6-2](#pone.0230156.g006){ref-type="fig"}.

(PDF)

###### 

Click here for additional data file.

###### Full blot images-[S3 Fig](#pone.0230156.s003){ref-type="supplementary-material"}.

(PDF)

###### 

Click here for additional data file.
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Dear Dr. Noda,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Academic Editor's comments:

1\) Why there is no LC3-I band in the LC3 blot? Considering the proximity of LC3-I and LC3-II bands, how can the authors be sure that the visible band is LC3-II?

2\) Total 4EBP1 should be analyzed together with phosphor-4EBP1.

Reviewer 1:

This manuscript by Ikari et al. describes the effects of TJ-35, a Kampo medicine herbal extract, on autophagy.  Upon starvation, TFEB and ULK dephosphorylation, as well as calcium concentration influx, were suppressed in the presence of TJ-35.  While these observations were interesting and potentially provide mechanistic insight on the action of TJ-35, there are some concerns that need to be addressed.

1\. All image quantification should be described in more detail: e.g. how many experiments were performed, how many cells were counted and quantified...

2\. ANOVA statistical analysis should be used for experimental groups \>2 in figs 2, 3, 4, 5, 7, 8.

3\. Many control experiments were missing.  e.g. Fig 2A, 2B should include DMEM+TJ-35, Fig 2C should include no treatment, as well as Bafilomycin A treatment alone; Figs 3A, 3B, 3C, 4A need DMEM+TJ-35.  These controls (or experimental) are important and can provide some useful information, especially considering TJ-35 was identified to have effects on tf-LC3 GFP/RFP ratio under medium rich (no starvation) condition in Fig 1B.

4\. Fig 2A, could the authors provide the RFP image (of tf-LC3) on each panel and analyze the ratio of GFP/RFP as well?  It can provide more information on which step autophagy is affected by TJ-35.

5\. Fig 4C, it's clear that TJ-35 had effect on TFEB dephosphorylation (based on the mobility shift). However, the effect on p-ULK1 was less obvious.  It should be normalized with total ULK1 (the amount of ULK1 was not equal among the samples).

6\. The title on Fig 8 legend is not appropriate.  "TJ-35 prevents starvation induced calcium influx from the ER mediated by the IP3 receptor", while this set of experiments did not involve TJ-35 at all.  

7\. In Fig 8, 0.5 micro M of EDTA was used to chelate calcium to conclude that the medium (or EBSS) was not the source of starvation-induced calcium influx.  However, the concentration of calcium in EBSS and DMEM is at the range of milli M, the EDTA added was not sufficient to chelate all the calcium.  Higher concentration of EDTA would need to be used for this experiment.  

8\. In Fig 6, have the authors tested if addition of TJ-35 has similar effect as cyclosporin A on inhibiting TFEB dephosphorylation through calcineurin? Similarly in Fig 7A, have the authors tested DMEM + ionomycin + TJ-35 condition?

Reviewer 2:

The report presents an interesting observation that "Shigyakusan" inhibits starvation-induced autophagy by promoting calcium dependent TFEB phosphorylation. Particularly, the elevation of cytosolic calcium upon starvation and involvement of ER calcium export to cytosol is exciting. The findings could be of interest to basic research in autophagy. However, more works needs to be carried out, this study could promise a discovery of novel autophagy modulator. For now, there are number of aspects that needs to be clarified before presentation in the PLOS One. Once these concerns are addressed, I recommend publication of this paper in PLOS One.

Major/Minor concerns are listed as follows.

1\) Authors should include the exact ratio in which the different ingredients of "Kampo" (at least of the Shigyakusan/TJ-35) has been prepared.

2\) Authors should explain on why they came up with certain concentration of positive control (Torin-1), negative control (Bafilomycin A) of autophagy for screening purpose. Importantly, author should explain how they choose specified concentration of each "Kampo" and how they were able to titrate its effect in relation to positive and negative control.

3\) Representative images of at least for Control, Torin-1, BafilomycinA and TJ-35 should be included from the screening results.

4\) After screening, authors already have an idea that autophagosome numbers might be decreased by TJ-35, therefore, authors should compare its effect with known inhibitors of autophagosome formation (possibly quantifying LC3 puncta). This is important to classify the effect of TJ-35 on autophagosome biogenesis. Comparing TJ-35 with the agents blocking autophagosome-lysosome fusion or agents preventing lysosomal acidification would only provide limited information that TJ-35 is an autophgay inhibitor as GFP/RFP intensity ratio is not affected by autophagosome population. Alternatively, authors should better show the GFP and RFP puncta per cell at least for Control, TJ-35, Torin-1, and Bafilomycin A.

5\) Combined effect of TJ-35 with Chloroquine or Bafilomycin A is needed to suggest that TJ-35 prevent autophagosome formation. (Possibly TJ-35 pre-treatment followed by addition of chloroquine or Bafilomycin A).

6\)  Is this effect of TJ-35 limited to starvation-induced autophagy?

7\) Why there is a difference in the band size of TFEB between 4th lane (DMEM+TJ-35) and 5th lane (EBSS+TJ-35) in the Figure 4C? In another word, is phosphorylation state of TFEB is different in DMEM+TJ-35 and EBSS+TJ-35? Overall, the blot shown in Figure 4C is confusing as authors claim that the difference in the size of TFEB represent its phosphorylation state? Is it because of shorter exposure time that both Phospho-TFEB and TFEB is not visible in this blot as shown in Figure 6 (Clearly, TFEB antibody could detect both phospho TFEB and TFEB)? Authors should either show the clear TFEB bands in the Figure 4C or perform cell fraction to show endogenous TFEB in cytosol or nucleus? Authors should explain, why there is strong dephosphorylation state of TFEB (if it is), in the 6th lane as compared with 3rd and 5th lane.

8\) Why 4EBP1 band size shown in the Figure 4C is different between samples (especially lane 4th, 5th and 6th? Does this antibody detect both phospho-EBP1 and total EBP1?

9\) Why there is discrepancy in the Ulk1 and S6k phosphorylation by TJ-35 in DMEM and EBSS as shown in Figure 4C? Could this data suggest that activity of TJ-35 on mTOR is dependent upon nutrient availability?

10\) Authors should explain the content of the reference\# 35 mentioned in the line\#349, page 14.

11\) How Inonomycin and cyclosporin A affect autophagy flux and mTOR activity? It has been reported that Ionomycin results in massive accumulation of autophagosome (Hansen M et al., Mol Cell 2007), could be a characteristic of impaired autophagy. It is important to show that how ionomycin and cyclosporinA affects autophagy flux by using tf-LC3 system. Could they do an assay to compare the effect of Ionomycin and Cyclosporin A with TJ-35, this could be important for the claim that TJ-35 inhibits calcium dependent autophagosome formation. 

12\) To support the conclusion drawn from Figure 8A, authors should include a calcium free medium in their experiment.

13\) I believe that it should be "calcium efflux from the ER" not "calcium influx from the ER" as mentioned in the line \#412, page 16. Author should correct this wherever possible in the manuscript text and figure legend.

14\) Authors should design an assay to conclude that the effect of the TJ-35 on autophagy activity requires all the five ingredients and try to explain why exact combination of all ingredient is essential. Alternatively, authors should perform assay to find out which ingredient of TJ-35 is most essential in modulating autophagy activity by applying the principle of exclusion and discuss the direction for identification/purification of novel molecules present in the ingredients of TJ-35 that could modulate calcium dependent autophagy.
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Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <http://journals.plos.org/plosone/s/competing-interests>
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This manuscript by Ikari et al. describes the effects of TJ-35, a Kampo medicine herbal extract, on autophagy. Upon starvation, TFEB and ULK dephosphorylation, as well as calcium concentration influx, were suppressed in the presence of TJ-35. While these observations were interesting and potentially provide mechanistic insight on the action of TJ-35, there are some concerns that need to be addressed.

1\. All image quantification should be described in more detail: e.g. how many experiments were performed, how many cells were counted and quantified,...

2\. ANOVA statistical analysis should be used for experimental groups 2 in figs 2, 3, 4, 5, 7, 8.

3\. Many control experiments were missing. e.g. Fig 2A, 2B should include DMEM+TJ-35, Fig 2C should include no treatment, as well as Bafilomycin A treatment alone; Figs 3A, 3B, 3C, 4A need DMEM+TJ-35. These controls (or experimental) are important and can provide some useful information, especially considering TJ-35 was identified to have effects on tf-LC3 GFP/RFP ratio under medium rich (no starvation) condition in Fig 1B.

4\. Fig 2A, could the authors provide the RFP image (of tf-LC3) on each panel and analyze the ratio of GFP/RFP as well? It can provide more information on which step autophagy is affected by TJ-35.

5\. Fig 4C, it's clear that TJ-35 had effect on TFEB dephosphorylation (based on the mobility shift). However, the effect on p-ULK1 was less obvious. It should be normalized with total ULK1 (the amount of ULK1 was not equal among the samples).

6\. The title on Fig 8 legend is not appropriate. "TJ-35 prevents starvation induced calcium influx from the ER mediated by the IP3 receptor", while this set of experiments did not involve TJ-35 at all.

7\. In Fig 8, 0.5 micro M of EDTA was used to chelate calcium to conclude that the medium (or EBSS) was not the source of starvation-induced calcium influx. However, the concentration of calcium in EBSS and DMEM is at the range of milli M, the EDTA added was not sufficient to chelate all the calcium. Higher concentration of EDTA would need to be used for this experiment.

8\. In Fig 6, have the authors tested if addition of TJ-35 has similar effect as cyclosporin A on inhibiting TFEB dephosphorylation through calcineurin? Similarly in Fig 7A, have the authors tested DMEM + ionomycin + TJ-35 condition?

Reviewer \#2: The report presents an interesting observation that "Shigyakusan" inhibits starvation-induced autophagy by promoting calcium dependent TFEB phosphorylation. Particularly, the elevation of cytosolic calcium upon starvation and involvement of ER calcium export to cytosol is exciting. The findings could be of interest to basic research in autophagy. However, more works needs to be carried out, this study could promise a discovery of novel autophagy modulator. For now, there are number of aspects that needs to be clarified before presentation in the PLOS One. Once these concerns are addressed, I recommend publication of this paper in PLOS One.

Major/Minor concerns are listed as follows.

1\) Authors should include the exact ratio in which the different ingredients of "Kampo" (at least of the Shigyakusan/TJ-

35\) has been prepared.

2\) Authors should explain on why they came up with certain concentration of positive control (Torin-1), negative control

(Bafilomycin A) of autophagy for screening purpose. Importantly, author should explain how they choose specified

concentration of each "Kampo" and how they were able to titrate its effect in relation to positive and negative control.

3\) Representative images of at least for Control, Torin-1, BafilomycinA and TJ-35 should be included from the screening

results.

4\) After screening, authors already have an idea that autophagosome numbers might be decreased by TJ-35, therefore,

authors should compare its effect with known inhibitors of autophagosome formation (possibly quantifying LC3 puncta).

This is important to classify the effect of TJ-35 on autophagosome biogenesis. Comparing TJ-35 with the agents blocking

autophagosome-lysosome fusion or agents preventing lysosomal acidification would only provide limited information

that TJ-35 is an autophgay inhibitor as GFP/RFP intensity ratio is not affected by autophagosome population.

Alternatively, authors should better show the GFP and RFP puncta per cell at least for Control, TJ-35, Torin-1, and

Bafilomycin A.

5\) Combined effect of TJ-35 with Chloroquine or Bafilomycin A is needed to suggest that TJ-35 prevent autophagosome

formation. (Possibly TJ-35 pre-treatment followed by addition of chloroquine or Bafilomycin A).

6\) Is this effect of TJ-35 limited to starvation-induced autophagy?

7\) Why there is a difference in the band size of TFEB between 4th lane (DMEM+TJ-35) and 5th lane (EBSS+TJ-35) in the

Figure 4C? In another word, is phosphorylation state of TFEB is different in DMEM+TJ-35 and EBSS+TJ-35? Overall, the

blot shown in Figure 4C is confusing as authors claim that the difference in the size of TFEB represent its

phosphorylation state? Is it because of shorter exposure time that both Phospho-TFEB and TFEB is not visible in this blot

as shown in Figure 6 (Clearly, TFEB antibody could detect both phospho TFEB and TFEB)? Authors should either show

the clear TFEB bands in the Figure 4C or perform cell fraction to show endogenous TFEB in cytosol or nucleus? Authors

should explain, why there is strong dephosphorylation state of TFEB (if it is), in the 6th lane as compared with 3rd and

5th lane.

8\) Why 4EBP1 band size shown in the Figure 4C is different between samples (especially lane 4th, 5th and 6th? Does this

antibody detect both phospho-EBP1 and total EBP1?

9\) Why there is discrepancy in the Ulk1 and S6k phosphorylation by TJ-35 in DMEM and EBSS as shown in Figure 4C?

Could this data suggest that activity of TJ-35 on mTOR is dependent upon nutrient availability?

10\) Authors should explain the content of the reference\# 35 mentioned in the line\#349, page 14.

11\) How Inonomycin and cyclosporin A affect autophagy flux and mTOR activity? It has been reported that Ionomycin

results in massive accumulation of autophagosome (Hansen M et al., Mol Cell 2007), could be a characteristic of

impaired autophagy. It is important to show that how ionomycin and cyclosporinA affects autophagy flux by using tf-

LC3 system. Could they do an assay to compare the effect of Ionomycin and Cyclosporin A with TJ-35, this could be

important for the claim that TJ-35 inhibits calcium dependent autophagosome formation.

12\) To support the conclusion drawn from Figure 8A, authors should include a calcium free medium

in their experiment.

13\) I believe that it should be "calcium efflux from the ER" not "calcium influx from the ER" as mentioned in the line \#412,

page 16. Author should correct this wherever possible in the manuscript text and figure legend.

14\) Authors should design an assay to conclude that the effect of the TJ-35 on autophagy activity requires all the five

ingredients and try to explain why exact combination of all ingredient is essential. Alternatively, authors should

perform assay to find out which ingredient of TJ-35 is most essential in modulating autophagy activity by applying the

principle of exclusion and discuss the direction for identification/purification of novel molecules present in the

ingredients of TJ-35 that could modulate calcium dependent autophagy.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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I have included this information in cover letter with attaching several figures.

January 17, 2020

MS ID\#: PONE-D-19-29517

Dr. Joerg Heber,

Editor-in-Chief

PLoS One

Dear Dr. Heber:

Please find enclosed the revised version of our manuscript, "Starvation-induced autophagy via calcium-dependent TFEB dephosphorylation is suppressed by Shigyakusan". We have responded to all concerns raised by the reviewers by performing a number of experiments.

Major changes from the previous version are: i) evaluation of the effects of each herbal ingredient (supplemental figure 4), ii) evaluation of the aggrephagy (Supplemental Figure 2), iii) effect of cyclosporin and ionomycin on autophagy (Supplemental Figure 7). We thank the reviewers for their constructive comments, due to which the quality of our data has improved.

We hope that these revisions are sufficient to make our manuscript suitable for publication in PLoS One.

Competing interests: Takeshi NODA has received research grant from Tsumura CO. LTD. Tsumura CO LTD has no role in the study design; collection, analysis, and interpretation of data; writing of the paper; and decision to submit for publication. This research is not related to any of employment, consultancy, patents, products in development of Tsumura CO. LTD. This does not alter the authors\' adherence to all the PLoS ONE policies on sharing data and materials. The other authors have nothing to disclose.

We have attached our point-by-point answers to the comments of the reviewers below.

Thank you for your consideration.

With regards,

Takeshi NODA, Ph.D. Professor,

Center for Frontier Oral Science,

Graduate School of Dentistry, Osaka University

1-8 Yamadaoka, Suita, Osaka 565-0871, Japan

E-mail: <takenoda@dent.osaka-u.ac.jp>

Tel: +81-6-6879-2976

Fax: +81-6-6879-2110

Academic Editor's comments:

1\) Why there is no LC3-I band in the LC3 blot? Considering the proximity of LC3-I and LC3-II bands, how can the authors be sure that the visible band is LC3-II?

Answer

HeLa cells are known to express less LC3-I. To substantiate this point, we compared the band pattern with the sample from MEF cells, which express more LC3-I. As shown in supplemental figure 3, the bands correspond to the LC3-II form but not LC3-I form.

2\) Total 4EBP1 should be analyzed together with phosphor-4EBP1.

Answer

We had shown total 4EBP1 with anti-4EBP1 antibody. Dephosphorylation is indicated by the down-shift of the band size.

Reviewer 1:

This manuscript by Ikari et al. describes the effects of TJ-35, a Kampo medicine herbal extract, on autophagy. Upon starvation, TFEB and ULK dephosphorylation, as well as calcium concentration influx, were suppressed in the presence of TJ-35. While these observations were interesting and potentially provide mechanistic insight on the action of TJ-35, there are some concerns that need to be addressed.

1\. All image quantification should be described in more detail: e.g. how many experiments were performed, how many cells were counted and quantified...

Answer

We have added the required information to the corresponding figure legends.

2\. ANOVA statistical analysis should be used for experimental groups \>2 in figs 2, 3, 4, 5, 7, 8.

Answer

We aimed to show the suppressive effect of TJ-35 only in the starvation condition; thus, we understand that it will be appropriate to use the t-test for comparison between 2 groups.

3\. Many control experiments were missing. e.g. Fig 2A, 2B should include DMEM+TJ-35, Fig 2C should include no treatment, as well as Bafilomycin A treatment alone; Figs 3A, 3B, 3C, 4A need DMEM+TJ-35. These controls (or experimental) are important and can provide some useful information, especially considering TJ-35 was identified to have effects on tf-LC3 GFP/RFP ratio under medium rich (no starvation) condition in Fig 1B.

Answer

According to this comment, we added control data in Figs. 2, 3. and 4. Especially, in Fig. 2C, we could not observe a significant effect in DMEM. It is possible that the 6-hour treatment may not be enough for the effect in DMEM. We will investigate this in our future studies.

4\. Fig 2A, could the authors provide the RFP image (of tf-LC3) on each panel and analyze the ratio of GFP/RFP as well? It can provide more information on which step autophagy is affected by TJ-35.

Answer

We have added RFP image and the signal ratio in Fig 2A. These data indicate that TJ-35 suppresses autophagosome and autolysosome induction. We examined which step is affected in the following experiments.

5\. Fig 4C, it's clear that TJ-35 had effect on TFEB dephosphorylation (based on the mobility shift). However, the effect on p-ULK1 was less obvious. It should be normalized with total ULK1 (the amount of ULK1 was not equal among the samples).

Answer

We here provided quantification data of ULK1 and phosphor-ULK1 and tubline. And also ULK1 blot was replaced with the same data but whose contrast is less exagerated. As suggested by the reviewer, the effect on ULK1 might be less noticeale. We still cannot provide the mechanism through which ULK1 phosphorylation is affected by TJ-35 and need to examine this in our future studies.

6\. The title on Fig 8 legend is not appropriate. "TJ-35 prevents starvation induced calcium influx from the ER mediated by the IP3 receptor", while this set of experiments did not involve TJ-35 at all.

Answer

According to this comment, we amended the title as follows: "Starvation induced calcium efflux from the ER mediated by the IP3 receptor".

7\. In Fig 8, 0.5 micro M of EDTA was used to chelate calcium to conclude that the medium (or EBSS) was not the source of starvation-induced calcium influx. However, the concentration of calcium in EBSS and DMEM is at the range of milli M, the EDTA added was not sufficient to chelate all the calcium. Higher concentration of EDTA would need to be used for this experiment.

Answer

Thanks for this comment. We noticed our mistake and have now amended it.

8\. In Fig 6, have the authors tested if addition of TJ-35 has similar effect as cyclosporin A on inhibiting TFEB dephosphorylation through calcineurin? Similarly in Fig 7A, have the authors tested DMEM + ionomycin + TJ-35 condition?

Answer

As shown in Fig. 6, TJ-35 did not exert a significant suppressive effect on the dephosphorylation of TFEB and nuclear translocation following ionomycin administration. However, due to an unknown reason, the combination of ionomycin and TJ-35 seems to affect the TFEB protein level. Since we cannot pursue this point in the current study, we will do so in a future study.

Reviewer 2:

The report presents an interesting observation that "Shigyakusan" inhibits starvation-induced autophagy by promoting calcium dependent TFEB phosphorylation. Particularly, the elevation of cytosolic calcium upon starvation and involvement of ER calcium export to cytosol is exciting. The findings could be of interest to basic research in autophagy. However, more works needs to be carried out, this study could promise a discovery of novel autophagy modulator. For now, there are number of aspects that needs to be clarified before presentation in the PLOS One. Once these concerns are addressed, I recommend publication of this paper in PLOS One.

Major/Minor concerns are listed as follows.

1\) Authors should include the exact ratio in which the different ingredients of "Kampo" (at least of the Shigyakusan/TJ-35) has been prepared.

Answer

According to this comment, we described the ingredient ratio of Shigyakusan in the Materials and Methods section.

2\) Authors should explain on why they came up with certain concentration of positive control (Torin-1), negative control (Bafilomycin A) of autophagy for screening purpose. Importantly, author should explain how they choose specified concentration of each "Kampo" and how they were able to titrate its effect in relation to positive and negative control.

Answer

We have added the following sentences on page 10, line 244

"To determine Torin-1 and Bafilomycin A concentration, we followed standard treatment conditions described previously \[21, 22\].

For determining Kampo concentration, we pre-screened small scale samples (20 samples) with different concentrations (100, 200, 400 �g/ml) and the concentration of 400 �g/ml exerted the most prominent effects; accordingly, we adopted it."

3\) Representative images of at least for Control, Torin-1, BafilomycinA and TJ-35 should be included from the screening results.

Answer

We have added the representative images in figure 1C.

4\) After screening, authors already have an idea that autophagosome numbers might be decreased by TJ-35, therefore, authors should compare its effect with known inhibitors of autophagosome formation (possibly quantifying LC3 puncta). This is important to classify the effect of TJ-35 on autophagosome biogenesis. Comparing TJ-35 with the agents blocking autophagosome-lysosome fusion or agents preventing lysosomal acidification would only provide limited information that TJ-35 is an autophgay inhibitor as GFP/RFP intensity ratio is not affected by autophagosome population. Alternatively, authors should better show the GFP and RFP puncta per cell at least for Control, TJ-35, Torin-1, and Bafilomycin A.

Answer

After screening, we postulated two possibilities, i.e., formation of autophagosome is suppressed or fusion/degradation is suppressed. If the former is correct, the latter need not be tested further. We examined several standard markers of autophagosome formation including Atg5, WIPI1, and ULK1, and all the resulting data indicated that autophagosome formation was suppressed. In the revised text, as suggested by the reviewer in comment 5, we added new data that LC3 puncta formation is suppressed by TJ-35 treatment even if autophagosome fusion/degradation is suppressed by bafilomycin treatment (supplemental figure 5). This also clearly supports that autophagosome formation is suppressed.

5\) Combined effect of TJ-35 with Chloroquine or Bafilomycin A is needed to suggest that TJ-35 prevent autophagosome formation. (Possibly TJ-35 pre-treatment followed by addition of chloroquine or Bafilomycin A).

Answer

As mentioned above, we added this experiment in supplemental figure 5, and it supports that autophagosome formation is suppressed by TJ-35 treatment.

6\) Is this effect of TJ-35 limited to starvation-induced autophagy?

Answer

Among the several types of autophagy, we further examined if TJ-35 affects aggrephagy, which targets protein aggregation. TJ-35 did not affect the efficiency of aggrephagy (supplemental figure 2). Therefore, we speculate that TJ-35 did not affect the broad range of autophagy.

7\) Why there is a difference in the band size of TFEB between 4th lane (DMEM+TJ-35) and 5th lane (EBSS+TJ-35) in the Figure 4C? In another word, is phosphorylation state of TFEB is different in DMEM+TJ-35 and EBSS+TJ-35? Overall, the blot shown in Figure 4C is confusing as authors claim that the difference in the size of TFEB represent its phosphorylation state? Is it because of shorter exposure time that both Phospho-TFEB and TFEB is not visible in this blot as shown in Figure 6 (Clearly, TFEB antibody could detect both phospho TFEB and TFEB)? Authors should either show the clear TFEB bands in the Figure 4C or perform cell fraction to show endogenous TFEB in cytosol or nucleus? Authors should explain, why there is strong dephosphorylation state of TFEB (if it is), in the 6th lane as compared Anwith 3rd and 5th lane.

Answer

Due to band intensity fluctuation, there may have been some confusion. We repeated the experiments, and succeeded in obtaining clearer and even intensity band profiles in figure 4D.

8\) Why 4EBP1 band size shown in the Figure 4C is different between samples (especially lane 4th, 5th and 6th? Does this antibody detect both phospho-EBP1 and total EBP1?

Answer

We are sorry for the shortcoming of the explanation. We added the following sentences on page 14, Line 360.

"Western blotting with anti-translation initiation factor 4E-binding protein (4EBP1) antibody reacted with both phosphorylated and unphosphorylated 4EBP1, with the latter represented by the down-shift of the band size. Dephosphorylation of 4EBP1 was also unaffected by TJ-35 (Fig 4E)."

9\) Why there is discrepancy in the Ulk1 and S6k phosphorylation by TJ-35 in DMEM and EBSS as shown in Figure 4C? Could this data suggest that activity of TJ-35 on mTOR is dependent upon nutrient availability?

Answer

Regarding S6k and 4EBP1, TJ-35 demonstrated no effect on its phosphorylation status by mTOR inactivation during starvation. We therefore suggest that TJ-35 effect is independent of mTOR activity.

10\) Authors should explain the content of the reference\# 35 mentioned in the line\#349, page 14.

Answer

Line \#349 would be referring to reference \#34, not \#35 of the original manuscript. We referred to this paper (current \#37) citing the physical interaction between s6k and mTOR.

11\) How Inonomycin and cyclosporin A affect autophagy flux and mTOR activity? It has been reported that Ionomycin results in massive accumulation of autophagosome (Hansen M et al., Mol Cell 2007), could be a characteristic of impaired autophagy. It is important to show that how ionomycin and cyclosporinA affects autophagy flux by using tf-LC3 system. Could they do an assay to compare the effect of Ionomycin and Cyclosporin A with TJ-35, this could be important for the claim that TJ-35 inhibits calcium dependent autophagosome formation.

According to this comment, we treated the cells with ionomycin and cyclosporin A to observe if any effects could be observed on autophagy. Hansen M et al, treated the cells with ionomycin for 24 hours, but it was highly toxic to cells, and hence, we treated them for 30 min. Ionomycin treatment in DMEM resulted in accumulation of GFP-LC3 similar to Hansen M, supporting a Ca-dependent autophagy induction mechanism. In addition, cyclosporin A treatment in EBSS reduced GFP-LC3 formation, supporting the positive role of calcineurin in autophagy induction. We added these data as supplemental figure 7.

12\) To support the conclusion drawn from Figure 8A, authors should include a calcium free medium in their experiment.

Answer

According to this comment, we used calcium free HBSS medium. As shown here, \[Ca\] still increased, supporting our conclusion that calcium is released from the intracellular pool. However, that condition seems to be relatively toxic to cells judged from cell morphology; therefore, we would not show this in the manuscript.

13\) I believe that it should be "calcium efflux from the ER" not "calcium influx from the ER" as mentioned in the line \#412, page 16. Author should correct this wherever possible in the manuscript text and figure legend.

Answer

According to this comment, we have corrected as "calcium efflux from the ER" in the line \#475, page 19

14\) Authors should design an assay to conclude that the effect of the TJ-35 on autophagy activity requires all the five ingredients and try to explain why exact combination of all ingredient is essential. Alternatively, authors should perform assay to find out which ingredient of TJ-35 is most essential in modulating autophagy activity by applying the principle of exclusion and discuss the direction for identification/purification of novel molecules present in the ingredients of TJ-35 that could modulate calcium dependent autophagy.

According to this comment, we prepared TJ-35 mixtures lacking each of the four herbal ingredients and observed its effect on autophagy. Omitting any of the four ingredients resulted in failure of suppression of autophagy, supporting that their combination is critical. We added these data as supplemental figure 4 and described it on page 11, line 284.

10.1371/journal.pone.0230156.r003
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Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No
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